**Appendix Table D110. Effectiveness of intensive pharmaceutical care campaign for migraine prevention in adults (results from low risk of bias randomized controlled clinical trial)214**

|  |  |  |  |
| --- | --- | --- | --- |
| **Definition of the Outcome** | **Mean [Standard Deviation]**  **with Intensive Pharmaceutical Care Campaign** | **Mean [Standard Deviation] with Usual Pharmacy Service** | **Reported Results** |
| 3 months: Incident users (No prescription 9 months before index date): Patients' triptan consumption (doses per month) | 2.5 [Not reported] | 2.5 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(2.45, 2.61), control=(2.29, 2.64) |
| 3 months: Prevalent users (One or more prescriptions 9 months before index date): Patients' triptan consumption (doses per month) | 7.1 [Not reported] | 7.1 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(6.66,7.51), control=(6.49,7.65) |
| 6 months: Incident users (No prescription 9 months before index date): Patients' triptan consumption (doses per month) | 1.3 [Not reported] | 1.3 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(1.21, 1.39), control=(1.19, 1.46) |
| 6 months: Prevalent users (One or more prescriptions 9 months before index date): Patients' triptan consumption (doses per month) | 5.3 [Not reported] | 5.3 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(5.04, 5.61), control=(4.75, 5.89) |
| 9 months: Incident users (No prescription 9 months before index date): Patients' triptan consumption (doses per month) | 0.8 [Not reported] | 0.8 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(0.73, 0.97), control=(0.78, 0.90) |
| 9 months: Prevalent users (One or more prescriptions 9 months before index date): Patients' triptan consumption (doses per month) | 4.2 [Not reported] | 4.3 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(3.89, 4.51), control=(3.87, 4.72) |
| 9 months: Prevalent users (One or more prescriptions 9 months before index date): <6 doses per month: Patients' triptan consumption (doses per month) | 3.0 [Not reported] | 3.0 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(2.78, 3.17), control=(2.71, 3.20) |
| 9 months: Prevalent users (One or more prescriptions 9 months before index date): ≥6 and <15 doses per month: Patients' triptan consumption (doses per month) | 9.9 [Not reported] | 9.3 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(9.3, 10.5), control=(10.4, 11.2) |
| 9 months: Prevalent users (One or more prescriptions 9 months before index date): ≥15 doses per month: Patients' triptan consumption (doses per month) | 25.4 [Not reported] | 26.0 [Not reported] | Geometric mean. Sample size for incident users: intervention=269 and control=348; 95% CI for intervention=(20.9, 31.0), control=(22.4, 30.1) |